Intellectia LogoIntellectia
Stock
Crypto
Features
Resources
Company
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo
StockCrypto

Features

Pre Market Movers
Financial AI Agent
Swing Trading
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
Stock Chart Patterns
Earnings Trading
AI Screener

Resources

Blog
Earnings
Partner Program

Company

Contact
About
News Release
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IPSC
    4. >
  4. Forecast

Stock Price Prediction

-
stocks logo
IPSC
-
$
0.000
0.000(0.000%)
    OverviewForecastTechnicalOptionsEarningsFinancialsValuationInsiders

IPSC Similar Chart Price Prediction

The price of IPSC is predicted to go up -3.09%, based on the high correlation periods with WKEY. The similarity of these two price pattern on the periods is 97.84%.

stocks logo

IPSC

stocks logo

WKEY

Down: -3.09%Similarity: 97.84%

IPSC Revenue Forecast

IPSC EPS Forecast

IPSC FAQs

What is bull’s view on IPSC?

IPSC stock is currently trading at $0.825, with analysts maintaining a bullish stance. The consensus price target is $8.50, implying a massive upside of over 900%, driven by strong buy ratings and optimism around its biotechnology pipeline. Recent developments, including Casdin Capital's increased stake and ongoing strategic reviews, further bolster the bull case.

What is bear's view on IPSC?

IPSC stock currently trades at $1.63, reflecting a recent 20.74% surge driven by Casdin Capital increasing its stake to 5.4%. Despite this, the termination of its collaboration with Bristol-Myers Squibb by March 2025 raises concerns about future partnerships and revenue streams. Analysts maintain a bullish outlook with a consensus price target of $8.50, suggesting significant upside potential.

What is IPSC revenue forecast for next quarter？

The market consensus for IPSC's revenue in the upcoming quarter is projected to be approximately $633.33K USD.

IPSC VS S&P500

Ask Intellectia about IPSC

IPSC Analyst's Forecast

Edward Tenthoff

Piper Sandler

Buy

Price Target

$12 → $4

Upside

+300%

Piper Sandler lowered the firm's price target on Century Therapeutics (IPSC) to $4 from $12 and keeps an Overweight rating on the shares. Century is conducting the Phase I CALiPSO-1 study of CNTY-101 in systemic lupus erythematosus, lupus nephritis, idiopathic inflammatory myopathy and diffuse cutaneous systemic sclerosis patients. Recent Phase I ELiPSE-1 data showed 1.0B CNTY-101 cells achieved ORR of 83%, including 2 CRs, 3 PRs, and 1 SD in B cell lymphoma patients with no GvHD or DLTs, the firm notes. Century expects to update ELiPSE-1 data in mid-2025. Bristol Myers (BMY) recently terminated the Century collaboration for CNTY-104 for AML and CNTY-106 for multiple myeloma effective March 12, 2025 due to portfolio prioritization, adds Piper.
Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Product
PricingPre Market MoversFinancial AI AgentSwing TradingStock Technical AnalysisStock MonitorCopy Top Investors PortfolioCrypto Technical Analysis
Support
BlogEarningsTerms of UsePrivacy PolicySitemapPartner Program
Start for Free